Clinical Trials Logo

Clinical Trial Summary

The efficacy and safety of chidamide in first-line maintenance therapy for PTCL will be assessed through a retrospective case analysis.


Clinical Trial Description

The study design belongs to a retrospective study, collecting information on patients with PTCL who were diagnosed and treated with chidamide as maintenance therapy at our center. The collected data includes age, gender, previous treatment regimens, results of auxiliary examinations (such as blood routine, biochemistry, bone marrow cytology, pathology, flow cytometry, NGS, etc.), as well as PET-CT images. The safety and efficacy of Chidemide as first-line maintenance therapy in PTCL will be analyzed. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05967949
Study type Observational
Source The First Affiliated Hospital with Nanjing Medical University
Contact wei xu
Phone +862568302182
Email xuwei10000@hotmail.com
Status Recruiting
Phase
Start date April 1, 2023
Completion date April 1, 2028

See also
  Status Clinical Trial Phase
Recruiting NCT03900442 - Phase 1 Study of PTX-100 in Patients With Advanced Malignancies With PTCL Expansion Cohort Phase 1
Withdrawn NCT02757248 - Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL Phase 1
Not yet recruiting NCT05238064 - Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCL Phase 1/Phase 2
Recruiting NCT03240211 - Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL Phase 1
Recruiting NCT04747236 - Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL Phase 2
Not yet recruiting NCT04705090 - A Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma Phase 2
Completed NCT03493451 - Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms Phase 2
Recruiting NCT03884205 - GDPE/CEOPE Compared With CEOPE for Newly Diagnosed Patients With PTCL